Innovation
Boston Biotech Rectify to Present Liver Drug Data at Denver Meeting
The company said Phase 1 results in cholestatic patients taking its oral candidate RTY-406 are expected in 2027.
American Association for the Study of Liver Diseases
Innovation
The company said Phase 1 results in cholestatic patients taking its oral candidate RTY-406 are expected in 2027.